Detection of erythropoietin misuse by the Athlete Biological Passport combined with reticulocyte percentage
DRUG TESTING AND ANALYSIS(2016)
摘要
The sensitivity of the adaptive model of the Athlete Biological Passport (ABP) and reticulocyte percentage (ret%) in detection of recombinant human erythropoietin (rHuEPO) misuse was evaluated using both a long-term normal dose and a brief high dose treatment regime. Sixteen subjects received either 65 IU rHuEPOxkg(-1) every second day for two weeks (normal-dose), 390 IU rHuEPOxkg(-1) on three consecutive days (high-dose), or frequent placebo treatment for 13 days in a randomized, placebocontrolled, double-blind crossover design. Blood variables were measured 4, 11, and 25 days following treatment initiation. The ABP based on haemoglobin concentration ([Hb]) and OFF-hr score ([Hb] -60 x root ret%) yielded atypical profiles following both normal-dose and high-dose treatment (0 %, 31 %, 13 % vs. 21 %, 33 %, 20 % at days 4, 11, and 25 after normal and high dose, respectively). Including ret% as a stand-alonemarker for atypical blood profiles increased (P<0.05) the sensitivity of the adaptive model at day 11 to 63 % and 67 % for normal-dose and high-dose rHuEPO administration, respectively. In conclusion, similar to 30 % of subjects injecting a normal-dose rHuEPO for two weeks or a high-dose rHuEPO for three days will present an atypical ABP profile. Including ret% as a stand-alone parameter improves the sensitivity two-fold. Copyright (C) 2015 John Wiley & Sons, Ltd.
更多查看译文
关键词
recombinant human erythropoietin,blood manipulation,doping control
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要